As a high-tech startup company in iPSCs disease modeling and drug screening platform area, Hopstem successfully held its first exhibition at the 2017 International Biomedical Innovation Summit. Besides showcases of our HopCell® products, we have also introduced our expertise in hiPSCs/hESCs differentiation, gene editing, cell banking and engineering, as well as new directions on cardio and liver cell differentiation. Our booth attracted a lot of attendees and many of them showed great interest with product inquiries and collaboration requests.
Hopstem Wins the Third Prize of VB-Link Competition
Huayi List: Hopstem Ranks Top 10 Most Promising Biotech Companies
The iPSC-derived Human Forebrain Neural Progenitor Cell Injection hNPC01 of Hopstem has Received CDE's Clinical Implication Approval
The launch meeting of the clinical research project of Hopstem hNPC01 universal cell therapy product for the treatment of stroke sequelae was successfully held.